Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pestronk

Showing results (141-150 of 151) with videos related to

Pageof 16
Sort By:
Neurology|March 1, 1993
Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months)R C Griggs, R T Moxley, J R Mendell, et al.
Annals of Neurology|October 1, 1986
Subacute sensory neuronopathy secondary to dorsal root ganglionitis in primary Sjögren's syndromeK Malinow, G D Yannakakis, S M Glusman, et al.
Neurology|July 28, 2004
Polymyositis: an overdiagnosed entityF W Miller, L G Rider, P H Plotz, et al.
Neurology|April 26, 2001
A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophyG M Fenichel, R C Griggs, J Kissel, et al.
Annals of Neurology|June 1, 1996
Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patientsF M Santorelli, M Sciacco, K Tanji, et al.
Neurology|March 31, 2012
Mutations in the tail domain of DYNC1H1 cause dominant spinal muscular atrophyM B Harms, K M Ori-McKenney, M Scoto, et al.
Molecular Genetics and Metabolism|December 26, 2001
Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementiaM J Kovach, B Waggoner, S M Leal, et al.
Neurology|August 5, 2011
Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial designR G Miller, D H Moore, D A Forshew, et al.
Neurology|July 15, 2011
Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophyD M Escolar, L P Hache, P R Clemens, et al.
Neurology|December 14, 2005
Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALSK L Ferrante, J Shefner, H Zhang, et al.
Pageof 16

Showing results (141-150 of 151) with videos related to

Sort By:
Pageof 16
Neurology|March 1, 1993
Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months)R C Griggs, R T Moxley, J R Mendell, et al.
Annals of Neurology|October 1, 1986
Subacute sensory neuronopathy secondary to dorsal root ganglionitis in primary Sjögren's syndromeK Malinow, G D Yannakakis, S M Glusman, et al.
Neurology|July 28, 2004
Polymyositis: an overdiagnosed entityF W Miller, L G Rider, P H Plotz, et al.
Neurology|April 26, 2001
A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophyG M Fenichel, R C Griggs, J Kissel, et al.
Annals of Neurology|June 1, 1996
Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patientsF M Santorelli, M Sciacco, K Tanji, et al.
Neurology|March 31, 2012
Mutations in the tail domain of DYNC1H1 cause dominant spinal muscular atrophyM B Harms, K M Ori-McKenney, M Scoto, et al.
Molecular Genetics and Metabolism|December 26, 2001
Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementiaM J Kovach, B Waggoner, S M Leal, et al.
Neurology|August 5, 2011
Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial designR G Miller, D H Moore, D A Forshew, et al.
Neurology|July 15, 2011
Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophyD M Escolar, L P Hache, P R Clemens, et al.
Neurology|December 14, 2005
Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALSK L Ferrante, J Shefner, H Zhang, et al.
Pageof 16